Liu Guangxian | Metabolomics | Best Researcher Award

Published on by Molecular Biologist

Mr. Liu Guangxian | Metabolomics | Best Researcher Award 

Deputy Director, at Institute of Agricultural Products Processing, Jiangxi Academy of Agricultural Sciences, China.

Dr. Guangxian Liu, a highly regarded molecular biologist, currently serves as Deputy Director at the Institute of Agricultural Products Processing, Jiangxi Academy of Agricultural Sciences. With a Ph.D. in Chemistry from Jiangxi Normal University, he specializes in agricultural product processing, food microbial fermentation, and protein modification. Renowned for integrating irradiation and glycosylation to reduce food allergenicity, Dr. Liu is a recipient of prestigious awards such as the Outstanding Young Agricultural Researcher Award and the Jiangxi Provincial Outstanding Youth Foundation. He leads innovative projects backed by the National Natural Science Foundation of China and other key funding agencies. A pioneer in asparagus deep-processing, he developed China’s first asparagus processing database and introduced over 20 novel products including asparagus baijiu and fermented juices. His work bridges cutting-edge science and industrial application, impacting food biotechnology nationally and globally. 🌱🧪

Professional Profile

Scopus

🎓 Education 

Dr. Guangxian Liu pursued his doctoral studies at Jiangxi Normal University, earning a Ph.D. in Chemistry. His academic journey was rooted in a deep passion for exploring molecular interactions within agricultural systems. During his doctoral tenure, he focused on the structural and chemical transformations of food proteins under various processing techniques. His education laid the groundwork for a career in interdisciplinary agricultural research, particularly in food biochemistry, allergen modification, and microbial fermentation. His exposure to advanced analytical methods, such as proteomics and irradiation-based food processing, positioned him to address global challenges in food safety and preservation. His academic training is further enriched by his participation in national and international research exchange programs, enhancing his ability to lead collaborative and innovative studies. 📘🔬

💼 Experience 

Dr. Liu has amassed over 15 years of experience in food science and agricultural processing, currently serving as Deputy Director at the Institute of Agricultural Products Processing, Jiangxi Academy of Agricultural Sciences. He has led several high-impact research initiatives funded by prominent agencies including the National Natural Science Foundation of China, Jiangxi Provincial R&D Programs, and the China Postdoctoral Science Foundation. Dr. Liu has extensive experience overseeing both basic and applied research, focusing on protein modification, food allergen reduction, and functional fermentation. His work has translated into patented innovations and industrial technologies, notably in asparagus processing. Additionally, he serves in editorial roles and collaborates with leading national laboratories such as the State Key Laboratory of Food Science at Nanchang University. His guidance has nurtured emerging talent while his strategic leadership has propelled Jiangxi’s agro-processing industry to new heights. 🏭📊

🔍 Research Interest 

Dr. Liu’s research interests revolve around agricultural product processing, food microbial fermentation, and protein modification at the molecular level. He is particularly focused on reducing allergenicity in food proteins through advanced modification techniques such as gamma irradiation and glycosylation, rooted in epitope shielding theory. His interests also include probiotic fermentation, antioxidant-enriched food production, and the valorization of local crops like asparagus through deep-processing technologies. Dr. Liu’s interdisciplinary approach connects molecular biology, food chemistry, and agricultural engineering, allowing for innovative product development. He has been instrumental in applying proteomic and structural biology tools to elucidate the mechanisms underlying protein desensitization and flavor formation in fermented foods. His dedication to translating lab-scale innovation into commercial applications showcases his vision for sustainable, health-enhancing food systems. 🧫🌾

🏆 Awards 

Dr. Guangxian Liu has received multiple honors for his innovative contributions to molecular food science. These include the Outstanding Young Agricultural Researcher Award, the Jiangxi Provincial Outstanding Youth Foundation, and selection for the China Association for Science and Technology’s Overseas Exchange Program for Outstanding Young Talents. These accolades underscore his exceptional impact in agricultural biotechnology and protein desensitization. His awards reflect not only scientific excellence but also his leadership in bridging research and practical industry application. Dr. Liu has also been recognized at provincial and national levels for his pioneering work on deep-processing technologies for local agricultural products such as asparagus. His recognition by funding bodies such as the National Natural Science Foundation of China and his inclusion in multiple provincial innovation programs further affirm his status as a trailblazer in applied molecular biosciences. 🥇🎖️

📚Top Noted Publications 

Dr. Liu has published widely in peer-reviewed journals such as Food Chemistry, Food Research International, Food Bioscience, and International Journal of Food Science and Technology. His research papers explore innovative topics in protein modification, microbial fermentation, and antioxidant mechanisms in food processing. Notable recent work includes his 2025 study on glycosylation-coupled irradiation to reduce allergenicity in egg proteins, contributing critical insights into epitope masking at a molecular level.

🔗 Selected Publications:

📘 1. Liu, G., et al. (2025).
Title: Shielding allergenic epitopes through glycosylation-irradiation synergy
Journal: Food Bioscience
Summary: This cutting-edge study explores a novel strategy combining glycosylation and Co-60 irradiation to modify food proteins in a way that masks or shields allergenic epitopes, significantly reducing allergenicity without compromising nutritional integrity. It opens promising avenues in hypoallergenic food development and personalized nutrition.
📑 Cited by: 8 articles
🔗 Link to article on ScienceDirect

🍹 2. Liu, G., et al. (2023).
Title: Microbial fermentation for enhanced antioxidant activity in asparagus juice
Journal: Food Research International
Summary: This study demonstrates how microbial fermentation—particularly using Lactobacillus strains—can be employed to enhance the antioxidant properties of asparagus juice. The research identifies optimal fermentation conditions, biochemical pathways, and the resulting increase in phenolic and flavonoid content, supporting functional beverage innovation.
📑 Cited by: 12 articles
🔗 Link to article on ScienceDirect

🧬 3. Liu, G., et al. (2022).
Title: Protein desensitization via Co-60 irradiation and conformational engineering
Journal: Food Chemistry
Summary: This foundational research explores how Co-60 gamma irradiation can alter protein structure at the molecular level, effectively reducing allergenic potential. It integrates conformational engineering with irradiation techniques, offering safe methods for food protein modification and allergen management.
📑 Cited by: 19 articles
🔗 Link to article on ScienceDirect

Conclusion 

Dr. Guangxian Liu is highly suitable and deserving of the Best Researcher Award under the International Molecular Biologist Awards. His sustained excellence in innovation, research leadership, and molecular-level insights into food processing position him as a pioneer in the cross-section of molecular biology and agricultural product development. His novel approaches to protein desensitization, fermentation biotechnology, and asparagus-based innovation have not only advanced science but also generated real-world applications. With minor enhancements in international collaboration and academic exposure, Dr. Liu’s trajectory promises even greater global impact.

Selim Sayın | Metabolomics | Best Researcher Award

Published on by Molecular Biologist

Dr. Selim Sayın | Metabolomics | Best Researcher Award 

Hematologist, at Gülhane Training And Research Hospital, Turkey.

Dr. Selim Sayın is a dedicated hematologist with a specialized focus in bone marrow transplantation and clinical hematology. Currently serving at the Gülhane Educational and Research Hospital in Ankara, he plays a pivotal role in the Hematology and Bone Marrow Transplantation Unit. His medical career spans over a decade, underpinned by a strong foundation in internal medicine and subspecialty training in hematology. Dr. Sayın is actively engaged in cutting-edge clinical trials involving immunotherapy and stem cell transplantation, contributing to the advancement of therapeutic strategies in hematologic diseases. Beyond clinical practice, he has co-authored several peer-reviewed publications and is a member of the Turkish Hematology Association. His commitment to evidence-based medicine and translational research ensures he remains at the forefront of hematologic innovation, delivering compassionate and high-quality care to his patients. 🩸📚

Professional Profile

Scopus

🎓 Education 

Dr. Sayın’s educational journey in medicine began at the Gülhane Military Medical Academy, where he completed his residency in Internal Medicine, laying a robust foundation for his future specialization. His interest in hematology and patient-centered cancer care led him to pursue a Hematology Fellowship at the Gülhane Educational and Research Hospital, a nationally recognized center for hematologic research and treatment. Through rigorous academic training and hands-on clinical exposure, Dr. Sayın developed expertise in managing complex hematological conditions, including leukemia, lymphoma, multiple myeloma, and bone marrow failure syndromes. His educational path reflects a commitment to lifelong learning and clinical excellence, further enhanced by continuous participation in international clinical trials and advanced training in bone marrow transplantation protocols. 🎓🔬

🏥 Experience 

Dr. Selim Sayın has amassed diverse experience across top-tier medical institutions in Turkey. His early professional years were spent at Çiğiltepe Askeri Dispanseri, where he honed his skills in general internal medicine and patient care. He later served at Keçiören Educational and Research Hospital, expanding his clinical scope and engaging in multidisciplinary hematology care. Currently, he holds a key position at Gülhane Educational and Research Hospital in Ankara within the Hematology and Bone Marrow Transplantation Unit. His role involves managing complex hematological malignancies, overseeing transplantation procedures, and mentoring junior medical staff. In all his professional endeavors, Dr. Sayın has consistently demonstrated a passion for precision medicine and patient safety. His multidisciplinary approach and adherence to evidence-based protocols underscore his standing as a leading figure in Turkish hematology. 🏨🧬

🔬 Research Interest 

Dr. Selim Sayın’s research interests lie at the intersection of clinical hematology, bone marrow transplantation, and immune thrombocytopenia therapies. He has been an active investigator in several multinational, Phase 3 clinical trials, including the ADVANCE trial (ARGX-113-1801), evaluating the efficacy and safety of Efgartigimod in treating adult primary immune thrombocytopenia. He also contributes to the ITHACA study, comparing novel therapies like isatuximab with standard regimens for high-risk smoldering multiple myeloma. His research is rooted in improving patient outcomes through tailored therapeutic approaches, biomarker-guided therapy, and apheresis-related innovations. Dr. Sayın is particularly interested in translational research that bridges the gap between clinical trials and routine patient care. His work consistently aims to redefine hematologic treatment standards, reflecting a commitment to innovation and scientific rigor. 🧪🧠

🏆 Awards 

Dr. Sayın has consistently demonstrated excellence in both clinical service and academic contribution, making him a strong nominee for prestigious hematology awards. While formal accolades are in progress, his impactful participation in high-profile, peer-reviewed research and international clinical trials distinguishes him in the field. As a co-author on multiple collaborative multicenter studies, he has earned recognition for innovative approaches to graft-versus-host disease prophylaxis and stem cell mobilization prediction models. His contributions reflect not only research excellence but also a dedication to improving quality of care in hematologic disorders. With ongoing involvement in pioneering trials and Turkish Hematology Association activities, Dr. Sayın is poised to receive further honors in clinical science and patient-focused research. 🥇📖

📄Top Noted Publications 

Dr. Sayın has co-authored impactful studies in leading journals, advancing knowledge in hematopoietic stem cell transplantation and therapeutic apheresis:

1. Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis After Allogeneic Stem Cell Transplantation

Journal: International Journal of Hematology-Oncology and Stem Cell Research, 2024, 18(3): 227–239
Summary:
This study evaluates the efficacy and safety of cyclophosphamide-based GVHD prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). It compares post-transplant cyclophosphamide (PTCy) protocols with conventional prophylactic regimens like calcineurin inhibitors (e.g., cyclosporine or tacrolimus) plus methotrexate.
Key outcomes analyzed include:

  • Incidence of acute and chronic GVHD

  • Relapse rates

  • Overall survival (OS)

  • Non-relapse mortality (NRM)

Findings:

  • PTCy significantly reduces grade II–IV acute GVHD incidence

  • Comparable relapse rates and OS

  • Better tolerability and lower infection rates in some subgroups

🔁 Cited by:
Recent articles on GVHD management strategies, especially those investigating low-toxicity prophylaxis regimens and haploidentical transplant protocols.

2. Apheresis Product Total CD34+ Cell Count Prediction at Peripheral Stem Cell Collection

Journal: Transplant Immunology, 2024, 86: 102111
Summary:
The paper introduces a predictive model for estimating total CD34+ cell yield in peripheral blood stem cell (PBSC) collections. It analyzes donor characteristics (e.g., age, weight, pre-apheresis CD34+ count) and apheresis parameters (blood volume processed, number of sessions) to develop a multivariable regression model.
Key contributions:

  • Establishes a practical tool for clinicians to predict yield

  • Optimizes collection strategies

  • Minimizes need for repeat apheresis sessions

Findings:

  • Pre-apheresis peripheral CD34+ count is the strongest predictor

  • Model accuracy validated across various donor groups

🔁 Cited by:
Papers on mobilization protocols, stem cell harvest optimization, and algorithmic prediction tools for transplant planning.

3. Therapeutic Apheresis Treatment in Rheumatic Diseases: Single-Center Experience

Journal: Therapeutic Apheresis and Dialysis, 2024
Summary:
This retrospective study presents a single-center experience of using therapeutic apheresis (primarily plasma exchange (PLEX) and immunoadsorption) in patients with rheumatic autoimmune diseases such as SLE, systemic sclerosis, and vasculitis.
It covers:

  • Indications for apheresis

  • Number of sessions per disease type

  • Clinical response rates and safety profiles

Findings:

  • High efficacy in crisis-phase autoimmune flares (e.g., lupus nephritis, ANCA vasculitis)

  • Apheresis well-tolerated with minimal complications

🔁 Cited by:
Clinical practice guidelines in autoimmune disease management, particularly regarding refractory cases or those unresponsive to immunosuppressants.

Conclusion

Dr. Selim Sayın demonstrates clear strengths as a clinician-scientist, particularly in collaborative, translational hematology research. His recent high-quality publications and participation in advanced clinical trials position him as a promising mid-career researcher. While his contributions are significant, to be a top-tier candidate for the Best Researcher Award, further development in leadership roles, independent authorship, and research visibility would strengthen his case.